Description

Gatifloxacin-d3 (hydrochloride) is the deuterium labeled Gatifloxacin (hydrochloride). Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.–Applications-COVID-19-anti-virus-Formula-C19H20D3ClFN3O4-Citation–References-[1]Daw-Garza A, et al. In vivo therapeutic effect of Gatifloxacin mesylate on BALB/c mice infected with Nocardia brasiliensis.Antimicrob Agents Chemother. 2008 Apr;52(4):1549-50.|[2]Fukuda H, et al. Antibacterial activity of Gatifloxacin hydrochloride (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother. 1998 Aug;42(8):1917-22.|[3]Takei M, et al. Inhibitory activities of Gatifloxacin hydrochloride (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.Antimicrob Agents Chemother. 1998 Oct;42(10):2678-81.|[4]Yamada C, et al. Gatifloxacin hydrochloride acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol. 2006 Dec 28;553(1-3):67-72. Epub 2006 Sep 28.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.-CASNumber–MolecularWeight-414.87-Compound Purity–SMILES-CC1NCCN(C2=C(F)C=C3C(N(C4CC4)C=C(C(O)=O)C3=O)=C2OC([2H])([2H])[2H])C1.Cl-Research_Area-Infection-Solubility-10 mM in DMSO-Target-Antibiotic;Bacterial;Isotope-Labeled Compounds;Topoisomerase-Isoform–Pathway-Anti-infection;Cell Cycle/DNA Damage;Others-MCE Product type-Isotope-Labeled Compounds